Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,864 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Prostatic Neoplasm
Interventions: Xofigo (Radium 223 dichloride,BAY88-8223); Drug
Lead sponsor: Bayer; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Multiple Myeloma
Interventions: Bortezomib, Lenalidomide, dexamethasone; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Depression
Interventions: Comprehensive Mental Health Services and Supports; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 16 Years to 24 Years
Enrollment: 782 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Albuterol Spiromax®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 30
States / cities: Phoenix, Arizona • Costa Mesa, California • Huntington Beach, California + 27 more

Conditions: Posttraumatic Stress Disorder, PTSD, Anxiety, Depression
Interventions: Transcranial Direct Current Stimulation (tDCS), Prolonged Exposure Therapy; Device · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Breast Cancer
Interventions: Ixabepilone, Trastuzumab, Carboplatin; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 12
States / cities: Fort Myers, Florida • Augusta, Georgia • Terre Haute, Indiana + 8 more

Conditions: Spinal Cord Injuries, Obesity, Cardiometabolic Syndrome
Interventions: Telenutrition; Behavioral
Lead sponsor: Santa Clara Valley Health & Hospital System; Other
Eligibility: 20 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Jose, California

Conditions: Physical Disability
Interventions: Intensity-controlled physical activity training (IPAT), Education and Access (EA); Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Pain
Interventions: Behavior Change Coaching, Nutrition, Autonomic Recalibration, Dry Needling, Osteopathic Manipulative Treatment, Counseling Psychology, Multiple Treatments; Behavioral · Other · Procedure
Lead sponsor: Edward Via Virginia College of Osteopathic Medicine; Other
Eligibility: 21 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Essential Tremor, Tremor
Interventions: Ethanol, Propranolol; Other · Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Myasthenia Gravis, Myasthenia Gravis, Juvenile Form, Myasthenia Gravis, Generalized
Interventions: Eculizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 8
States / cities: Los Angeles, California • Tampa, Florida • Chicago, Illinois + 5 more

Conditions: Neurogenic Bladder Disorder, Lower Urinary Tract Disorder, Urinary Tract Infection (Diagnosis)
Interventions: urine Resazurin Reduction Ratio, USQNB; Diagnostic Test · Other
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: EUR-1008 (APT-1008), Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Tyler, Texas

Conditions: Chronic Ankle Instability
Interventions: Ankle Joint Mobilization, Foot Massage, Calf Stretching; Other
Lead sponsor: Joel Thompson; Other
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Ithaca, New York • Charlotte, North Carolina

Conditions: Inflammation, Hypertriglyceridemia, Metabolic Disease, Lipid Metabolism Disorder, Hyperlipidemias, Bile Acid Malabsorption
Interventions: Lentil, Control; Behavioral
Lead sponsor: Montana State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Systolic Heart Failure
Interventions: Probenecid 1 gr oral twice daily, Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Volunteers
Interventions: Maribavir Commercial Tablet Formulation, Maribavir Pediatric Powder-for-oral Suspension Formulation, Rabeprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Chronic Pancreatitis, Pancreatitis
Interventions: TEA; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Autoimmune Encephalitis
Interventions: Ocrelizumab, Saline; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Primary Spontaneous Pneumothorax
Interventions: Autologous Blood Patch; Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 13 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dense Deposit Disease, Membranoproliferative Glomerulonephritis
Interventions: Eculizumab; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: New York, New York

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 11
States / cities: Anaheim, California • Los Angeles, California • Panama City, Florida + 8 more

Conditions: Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: Concizumab; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Male only
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 7
States / cities: Orange, California • Atlanta, Georgia • Indianapolis, Indiana + 4 more

Search by objective public record fields.

Treatment Patterns in Metastatic Prostate Cancer

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

Addressing Mental Health in African American Job Training Adolescents and Young Adults

Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

TDCS-Augmented Prolonged Exposure Therapy

Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer

Telenutrition for Individuals With SCI

Wheelchair User Physical Activity Training Intervention to Enhance Cardiometabolic Health

VCOM Pain Free Research Collaborative

Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

Rapid UTI Diagnostics in Lower Urinary Tract Dysfunction Among Catheter Users

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Sensory-Targeted Ankle Rehabilitation Strategies (STARS)

Impact of Foods on Bile Acids, Metabolites, and Inflammation

Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure

A Study of Maribavir Pediatric Formulation in Healthy Adult Participants

Role of Home-Based Transcutaneous Electrical Acustimulation for Treatment of Pain in Subjects With Chronic Pancreatitis

Efficacy of Ocrelizumab in Autoimmune Encephalitis

Autologous Blood Patch for Primary Spontaneous Pneumothorax

Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy

Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab

Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors